Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Novel Format Conjugates Summit in Boston

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Dec 21, 2021 9:43am

101 Views

Post# 34249985

RE:RE:Novel Format Conjugates Summit in Boston

Maybe that would be a nice time to get some early data on some of the newer R&D constructs like SN38 or an siRNA version. Hopefully the clinical stuff runs to a different beat.

I'm excited to see if they truly can deliver sufficient active siRNA via the Sortilin receptor. That would really stretch the possibilities. Maybe they can deliver that piece of news in 2022.

SPCEO1 wrote: April 25-27th - I hope we don't have to wait that long to hear a good word from TH on Sort1+. we probably will not and one has to think their confidence level is growing since they are doing such presentations. I worry that we have been suffering from confirmation bias when looking at the various hints on TH-1902's progress and seeing what we want ot see while the company says nothing straightforwardly about the phase 1a trial. But when I see them signing up for a presentation like this, it shows they are preparing to speak more about it post the TH-1902 phase 1a trial, which is encouraging. We still might befalling into the conformation bias hole but maybe not down as far as before.

scarlet1967 wrote:
SORT1+ TechnologyTM Platform & Novel Peptide Drug Conjugates (PDC’s) Targeting Sortilin (SORT1)

Christian Marsolais
Chief Medical Officer & Vice President of Medical Affairs, Theratechnologies

Synopsis

Learn about the Sortilin receptor, its role in the normal cell and how its role and function change in cancer

Understand why sortilin is an important biomarker/target in cancer, it expression levels in solid tumors, how it can be used for novel drug delivery and why it is an ideal candidate for internalization of novel peptide drug conjugates (PDC’s)

Evaluate Sortilin’s unique structure and MOA, leading to rapid internalization into the cancer cells and delivery of less toxic payloads with better efficacy and safety profiles. Preclinical data will be discussed to demonstrate the efficacy and safety of Thera’s lead PDC candidate, TH1902, across multiple solid tumors and an update on the ongoing clinical FIH trial will be given.

Review the potential of this novel SORT1+ platform for future developments

https://novel-format-conjugates.com/whats-on/day-two/